Bayer’s long-term commitment to family planning is reinforced in accordance with the Programme of Action of the Nairobi summit (ICPD25). The company has been supporting family-planning programs with a broad range of hormonal contraception methods for many years, including oral contraceptives, monthly and thrice-monthly injections and implants 1. Low- and low-middle-income countries have seen increasing demand for contraception, particularly long-acting, reversible contraceptives (LARCs), including implants
By providing immediate solutions to solve urgent problems as well as long-term structural proficiency, Bayer strengthens UNFPA’s humanitarian response.
Bayer’s expertise and innovation within supply chains and medical logistics help support UNFPA’s country offices in overcoming bottlenecks related to COVID-19 and improving logistics measures to maintain the quality of pharmaceutical supplies.
The partnership also focuses on supplies provided in the Interagency Emergency Reproductive Health (IARH) kits as well as on improving the clinical practices of service providers.
The company’s medical logistics and know-how will help UNFPA to strengthen its supply chain management and the use of pharmaceuticals during humanitarian crises in a sustainable manner.
Bayer has recently committed$1 million $500,000 and products worth $3.8 million to the UNFPA Supplies Partnership, which seeks to secure the essential contraceptive supplies and maternal health medicines required by millions of women and adolescent girls over the next decade. Bayer’s contribution will help prevent almost 215,000 unintended pregnancies, 5,000 maternal and child deaths, and over 58,000 unsafe abortions in Chad, the Democratic Republic of the Congo, Ethiopia, Lesotho, Mali, Mauritania, Niger, Nigeria, Papua New Guinea, the Republic of the Congo, Somalia, Yemen, Zambia and Zimbabwe.
1By 2030, we are committed to providing 100 million women in low- and middle-income countries with access to modern contraception. Bayer AG. 13 October 2021. Available at: https://www.bayer.com/en/pharma/empowering-women-globally Last accessed: November 2021.
2Harrison, M.S., Goldenberg, R.L. Immediate postpartum use of long-acting reversible contraceptives in low- and middle-income countries. matern health, neonatol and perinatol 3, 24 (2017). https://doi.org/10.1186/s40748-017-0063-z